3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lymphoma, Non-Hodgkin
3
Carcinoma, Non-Small-Cell Lung
3
Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Leukemia, Hairy Cell
2
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Noonan syndrome 3
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Medulloblastoma
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Hepatoblastoma
1
Glioma
1
Genomic Instability
1
Ependymoma
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
ruxolitinib
13
Cyclophosphamide
5
Tacrolimus
4
fludarabine phosphate
3
Whole-Body Irradiation
3
Stem Cell Transplantation
3
Specimen Handling
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Cyclosporine
3
fludarabine
2
fedratinib
2
Sirolimus
2
Injections
2
Busulfan
2
Biopsy
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
veliparib
1
umbralisib
1
thymoglobulin
1
selinexor
1
reparixin
1
piperine
1
pegylated granulocyte colony-stimulating factor
1
navitoclax
1
luspatercept
1
letermovir
1
itacitinib
1
iadademstat
1
demethoxycurcumin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
Vemurafenib
×
90 days
×
Clear all
No trials found.